ClinicalTrials.gg
CompletedNCT02525094ALLEVIADUpdated Feb 15, 2018Results posted

Phase 2a Study to Evaluate the Efficacy and Safety of MEDI9929 in Adults With Atopic Dermatitis

A Phase 2 interventional study of MEDI9929 and Placebo in Atopic Dermatitis, sponsored by MedImmune LLC. Completed at 29 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-02-15.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
251st of 544
113 · median 96
Started
2015
with 25 others
Phase 2
202 of 639
18 open now
Registered
169th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 251st largest by enrollment of the 544 interventional ones that give a count, is one of 26 that started in 2015, is one of 202 in phase 2, and was the 169th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

To assess the efficacy and safety of MEDI9929 in adult subjects with Atopic Dermatitis

Read the detailed description

This is a Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of MEDI9929 administered subcutaneously to adult subjects with moderate to severe Atopic Dermatitis. Subjects will be randomized in a 1:1 fashion and will be stratified at screening. Approximately 100 subjects are planned to be randomized at approximately 35 sites in 6 countries

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Eczema
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • AD meeting Hanifin and Rajka criteria
  • Age 18-75 years inclusive at screening
  • Atopic dermatitis that affects greater than/equal to 10% body surface area
  • Moderate to severe AD
  • Effective in line with protocol details

Exclusion criteria

Exclusion Criteria:

  • Active dermatologic conditions which may confuse the diagnosis of Atopic Dermatitis
  • , C or
  • Pregnant or breastfeeding
  • History of anaphylaxis following any biologic therapy
  • History of infections within 4 weeks prior to Visit 3
  • Diagnosis of helminth parasitic infection within 6 months to screening
  • History of Cancer except basal cell
  • Receipt of any marketed or biologic agent within 4 months to visit 3
  • Any clinically relevant abnormal finding
  • Major surgery within 8 weeks prior to Visit 1
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    MEDI9929 280 mg

    Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.

    Biological: MEDI9929

  • Placebo comparator
    Placebo

    Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.

    Biological: Placebo

Interventions

  • BiologicalMEDI9929

    Participants will receive 6 subcutaneous doses of MEDI9929 280 mg every 2 weeks for 12 weeks, with the last dose at Week 10.

  • BiologicalPlacebo

    Participants will receive 6 subcutaneous doses of placebo every 2 weeks for 12 weeks, with the last dose at Week 10.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction From Baseline in Eczema Area and Severity Index (EASI 50) at Week 12

    The eczema area and severity index (EASI) evaluates 4 natural anatomical regions for severity (0 \[none\] to 3 \[severe\]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The total score is the sum of the four body-region scores, maximum=72, minimum=0. The higher values indicating more severe disease. The EASI50 responder defined as a participant who achieved at least 50% reduction in EASI score from baseline.

    Time frame: Baseline (Day 1) and Week 12

Secondary outcomes

  1. Percentage of Participants Achieving >= 75 % Reduction From Baseline in EASI75 at Week 12

    The EASI evaluates 4 natural anatomical regions for severity (0 \[none\] to 3 \[severe\]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The total score is the sum of the four body-region scores, maximum=72, minimum=0. The higher values indicating more severe disease. The EASI75 responder defined as a participant who achieves at least a 75% reduction in EASI score from baseline.

    Time frame: Baseline (Day 1) and Week 12

  2. Mean Change From Baseline in EASI Total Score at Week 12

    The EASI evaluates 4 natural anatomical regions for severity (0 \[none\] to 3 \[severe\]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The total score is the sum of the four body-region scores, maximum=72, minimum=0. The higher values indicating more severe disease.

    Time frame: Baseline (Day 1) and Week 12

  3. Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 0 (Clear) or 1 (Almost Clear) and at Least a 2-Grade Reduction From Baseline

    The investigator's global assessment (IGA) allows investigators to assess overall disease severity at one given time point and consists of a 5-point severity scale from clear to severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, and 4 = severe disease). A participant has IGA response if they achieve a score of 0 (clear) or 1 (almost clear) and at least a 2-grade reduction from baseline.

    Time frame: Baseline (Day 1) and Week 12

  4. Mean Change From Baseline in the Scoring of Atopic Dermatitis (SCORAD) at Week 12

    The scoring of atopic dermatitis (SCORAD) is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms. The range of the SCORAD is 0-103, where 0 indicates no eczema. The higher values indicating more severe disease.

    Time frame: Baseline (Day 1) and Week 12

  5. Percentage of Participants Achieving >= 50% Reduction From Baseline in SCORAD 50

    The SCORAD is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms. The range of the SCORAD is 0-103, where 0 indicates no eczema. The higher values indicating more severe disease. The SCORAD 50 responder defined as a participant who achieves at least a 50% reduction in SCORAD score from baseline.

    Time frame: Baseline (Day 1) and Week 12

  6. Percentage of Participants Achieving >= 75% Reduction From Baseline in SCORAD 75

    The SCORAD is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms. The range of the SCORAD is 0-103, where 0 indicates no eczema. The higher values indicating more severe disease. The SCORAD 75 responder is defined as a participant who achieves at least a 75% reduction in SCORAD score from baseline.

    Time frame: Baseline (Day 1) and Week 12

  7. Mean Change From Baseline in Average Pruritus Numeric Rating Scale (NRS) at Week 12

    Pruritus is assessed using an Numeric Rating Scale (NRS) (0 - 10) with 0= no itch and 10= worst imaginable itch. Daily pruritus assessments were summarized as weekly peak score and a change from baseline in weekly peak score was calculated.

    Time frame: Baseline (Day 1) and Week 12

  8. Mean Change From Baseline in 5-D Pruritus Score at Week 12

    The 5-D pruritus scale is a brief questionnaire designed to assess itch. This scale takes into account the multidimensional nature of pruritus, its impact on quality of life, and is capable of detecting change over time. The 5-D pruritus scale included 5 domains (duration, degree, direction, disability, and distribution of pruritus). The total 5-D score was obtained by scoring each of the domains separately and then summing them together. 5-D total scores ranged between 5 (no pruritus) and 25 (most severe pruritus). The higher values indicating more severe pruritus.

    Time frame: Baseline (Day 1) and Week 12

  9. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An Adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of investigational product, whether or not considered related to investigational product. Serious adverse event is any AE that resulted in:death;inpatient hospitalization or prolongation of existing hospitalization;persistent or significant disability or incapacity;is life-threatening;is a congenital anomaly/birth defect in offspring of a study participant;or was an important medical event that may not have resulted in death, threatened life,or required hospitalization and that, based on appropriate medical judgment, may have jeopardized participant and may have required medical or surgical intervention to prevent one of outcomes above. TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug until Week 22.

    Time frame: From treatment administration (Day1) to 22 weeks

  10. Mean Trough Serum Concentration of MEDI9929

    The mean serum concentrations of MEDI9929 was observed at specified timepoints.

    Time frame: Week 0 (Pre dose), Weeks 4, 8, and 12 (post dose)

  11. Number of Participants Who Developed Detectable MEDI9929 Anti-drug Antibodies

    A participant was considered ADA-positive across the study if they had a positive reading (titer of 50 or higher) at any time point during the study period.

    Time frame: Baseline (Day 1) to Week 22

07

Results

Posted Feb 15, 2018

Participant flow

The study was conducted from 15Aug2015 to 15Jul2016.

Participant flow — Overall Study
MilestonePlaceboMEDI9929 280 mg
Started5756
Treated5655
Completed4948
Not completed88
Withdrew: Lost to follow-up21
Withdrew: Withdrawal by subject56
Withdrew: Not treated11

Outcome measures

PrimaryPercentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction From Baseline in Eczema Area and Severity Index (EASI 50) at Week 12

The eczema area and severity index (EASI) evaluates 4 natural anatomical regions for severity (0 \[none\] to 3 \[severe\]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The total score is the sum of the four body-region scores, maximum=72, minimum=0. The higher values indicating more severe disease. The EASI50 responder defined as a participant who achieved at least 50% reduction in EASI score from baseline.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction From Baseline in Eczema Area and Severity Index (EASI 50) at Week 12
Percentage of participantsPlaceboMEDI9929 280 mg
Percentage of Participants Achieving Greater Than or Equal to (>=) 50 Percent (%) Reduction From Baseline in Eczema Area and Severity Index (EASI 50) at Week 1248.264.7
Statistical analysis
  • Placebo vs MEDI9929 280 mg · Odds ratio (or): 1.97 · 95% CI 0.90 to 4.33
SecondaryPercentage of Participants Achieving >= 75 % Reduction From Baseline in EASI75 at Week 12

The EASI evaluates 4 natural anatomical regions for severity (0 \[none\] to 3 \[severe\]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The total score is the sum of the four body-region scores, maximum=72, minimum=0. The higher values indicating more severe disease. The EASI75 responder defined as a participant who achieves at least a 75% reduction in EASI score from baseline.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving >= 75 % Reduction From Baseline in EASI75 at Week 12
Percentage of participantsPlaceboMEDI9929 280 mg
Percentage of Participants Achieving >= 75 % Reduction From Baseline in EASI75 at Week 1219.824.4
SecondaryMean Change From Baseline in EASI Total Score at Week 12

The EASI evaluates 4 natural anatomical regions for severity (0 \[none\] to 3 \[severe\]) and extent of key disease signs and focuses on the key acute and chronic signs of inflammation (erythema, induration/papulation, excoriation, and lichenification). The total score is the sum of the four body-region scores, maximum=72, minimum=0. The higher values indicating more severe disease.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · units on a scale
Mean Change From Baseline in EASI Total Score at Week 12
units on a scalePlaceboMEDI9929 280 mg
Baseline24.48 ± 11.2124.05 ± 12.38
Week 12-11.23 ± 8.73-12.16 ± 9.96
SecondaryPercentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 0 (Clear) or 1 (Almost Clear) and at Least a 2-Grade Reduction From Baseline

The investigator's global assessment (IGA) allows investigators to assess overall disease severity at one given time point and consists of a 5-point severity scale from clear to severe disease (0 = clear, 1 = almost clear, 2 = mild disease, 3 = moderate disease, and 4 = severe disease). A participant has IGA response if they achieve a score of 0 (clear) or 1 (almost clear) and at least a 2-grade reduction from baseline.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 0 (Clear) or 1 (Almost Clear) and at Least a 2-Grade Reduction From Baseline
Percentage of participantsPlaceboMEDI9929 280 mg
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of 0 (Clear) or 1 (Almost Clear) and at Least a 2-Grade Reduction From Baseline12.819.3
SecondaryMean Change From Baseline in the Scoring of Atopic Dermatitis (SCORAD) at Week 12

The scoring of atopic dermatitis (SCORAD) is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms. The range of the SCORAD is 0-103, where 0 indicates no eczema. The higher values indicating more severe disease.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · units on a scale
Mean Change From Baseline in the Scoring of Atopic Dermatitis (SCORAD) at Week 12
units on a scalePlaceboMEDI9929 280 mg
Baseline58.66 ± 13.3257.68 ± 14.80
Week 12-19.35 ± 17.49-24.24 ± 16.94
SecondaryPercentage of Participants Achieving >= 50% Reduction From Baseline in SCORAD 50

The SCORAD is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms. The range of the SCORAD is 0-103, where 0 indicates no eczema. The higher values indicating more severe disease. The SCORAD 50 responder defined as a participant who achieves at least a 50% reduction in SCORAD score from baseline.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving >= 50% Reduction From Baseline in SCORAD 50
Percentage of participantsPlaceboMEDI9929 280 mg
Percentage of Participants Achieving >= 50% Reduction From Baseline in SCORAD 5029.441.0
SecondaryPercentage of Participants Achieving >= 75% Reduction From Baseline in SCORAD 75

The SCORAD is a clinical tool for assessing the severity (that is, extent, intensity) of atopic dermatitis (AD). The tool evaluates the extent and intensity of the AD lesions, along with participant symptoms. The range of the SCORAD is 0-103, where 0 indicates no eczema. The higher values indicating more severe disease. The SCORAD 75 responder is defined as a participant who achieves at least a 75% reduction in SCORAD score from baseline.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving >= 75% Reduction From Baseline in SCORAD 75
Percentage of participantsPlaceboMEDI9929 280 mg
Percentage of Participants Achieving >= 75% Reduction From Baseline in SCORAD 757.49.8
SecondaryMean Change From Baseline in Average Pruritus Numeric Rating Scale (NRS) at Week 12

Pruritus is assessed using an Numeric Rating Scale (NRS) (0 - 10) with 0= no itch and 10= worst imaginable itch. Daily pruritus assessments were summarized as weekly peak score and a change from baseline in weekly peak score was calculated.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · units on a scale
Mean Change From Baseline in Average Pruritus Numeric Rating Scale (NRS) at Week 12
units on a scalePlaceboMEDI9929 280 mg
Baseline5.15 ± 2.105.26 ± 2.02
Week 12-1.39 ± 1.93-1.90 ± 1.99
SecondaryMean Change From Baseline in 5-D Pruritus Score at Week 12

The 5-D pruritus scale is a brief questionnaire designed to assess itch. This scale takes into account the multidimensional nature of pruritus, its impact on quality of life, and is capable of detecting change over time. The 5-D pruritus scale included 5 domains (duration, degree, direction, disability, and distribution of pruritus). The total 5-D score was obtained by scoring each of the domains separately and then summing them together. 5-D total scores ranged between 5 (no pruritus) and 25 (most severe pruritus). The higher values indicating more severe pruritus.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · units on a scale
Mean Change From Baseline in 5-D Pruritus Score at Week 12
units on a scalePlaceboMEDI9929 280 mg
Baseline16.7 ± 3.716.0 ± 3.7
Week 12-3.9 ± 4.5-3.6 ± 4.4
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An Adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of investigational product, whether or not considered related to investigational product. Serious adverse event is any AE that resulted in:death;inpatient hospitalization or prolongation of existing hospitalization;persistent or significant disability or incapacity;is life-threatening;is a congenital anomaly/birth defect in offspring of a study participant;or was an important medical event that may not have resulted in death, threatened life,or required hospitalization and that, based on appropriate medical judgment, may have jeopardized participant and may have required medical or surgical intervention to prevent one of outcomes above. TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug until Week 22.

Time frame:
From treatment administration (Day1) to 22 weeks
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsPlaceboMEDI9929 280 mg
TEAEs4038
TESAEs32
SecondaryMean Trough Serum Concentration of MEDI9929

The mean serum concentrations of MEDI9929 was observed at specified timepoints.

Time frame:
Week 0 (Pre dose), Weeks 4, 8, and 12 (post dose)
Reported as:
Mean · mcg/mL
Mean Trough Serum Concentration of MEDI9929
mcg/mLMEDI9929 280 mg
Week 0NA ± NA
Week 434.7 ± 10.9
Week 850.5 ± 17.5
Week 1254.9 ± 21.5
SecondaryNumber of Participants Who Developed Detectable MEDI9929 Anti-drug Antibodies

A participant was considered ADA-positive across the study if they had a positive reading (titer of 50 or higher) at any time point during the study period.

Time frame:
Baseline (Day 1) to Week 22
Reported as:
Count of participants · Participants
Number of Participants Who Developed Detectable MEDI9929 Anti-drug Antibodies
ParticipantsPlaceboMEDI9929 280 mg
Baseline21
Week 2220

Adverse events

Collected over From treatment administration (Day1) to 22 weeks. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/55 (5.5%)33/55 (60%)
MEDI9929 280 mg—2/56 (3.6%)29/56 (51.8%)
Most frequent serious events
Most frequent serious events
EventPlaceboMEDI9929 280 mg
Chest painGeneral disorders1/550/56
CellulitisInfections and infestations1/550/56
SyncopeNervous system disorders1/550/56
Dermatitis atopicSkin and subcutaneous tissue disorders1/551/56
Infected dermal cystInfections and infestations0/551/56
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPlaceboMEDI9929 280 mg
NasopharyngitisInfections and infestations11/5513/56
Upper respiratory tract infectionInfections and infestations7/551/56
Dermatitis atopicSkin and subcutaneous tissue disorders7/555/56
DiarrhoeaGastrointestinal disorders3/555/56
Injection site erythemaGeneral disorders0/553/56
HeadacheNervous system disorders1/553/56
CellulitisInfections and infestations2/550/56
SinusitisInfections and infestations2/552/56
ArthralgiaMusculoskeletal and connective tissue disorders2/551/56
RashSkin and subcutaneous tissue disorders2/550/56

Baseline characteristics

Intent-To-Treat (ITT) population included all participants who were randomized and received any study investigational product.

Age, Continuous
Age, Continuous(Years)PlaceboMEDI9929 280 mgTotal
Mean38.8 ± 15.338.5 ± 14.938.7 ± 15.0
Age, Customized
Age, Customized(Participants)PlaceboMEDI9929 280 mgTotal
18-35 years282755
36-75 years282856
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboMEDI9929 280 mgTotal
Female262349
Male303262
Eczema Area and Severity Index Score
Eczema Area and Severity Index Score(Participants)PlaceboMEDI9929 280 mgTotal
<= 25 points363369
> 25 points202242
Investigator's Global Assessment
Investigator's Global Assessment(Participants)PlaceboMEDI9929 280 mgTotal
Category 2011
Category 3464490
Category 4101020
Atopic Dermatitis Status
Atopic Dermatitis Status(Participants)PlaceboMEDI9929 280 mgTotal
IgE >= 150 kU/L and Positive Serum Specific IgEa504797
IgE >= 150 kU/L and Negative Serum Specific IgE202
IgE < 150 kU/L and Positive Serum Specific IgE336
IgE < 150 kU/L and Negative Serum Specific IgEb134
Missing022
08

Study locations

29 sites
  • Research Site
    North Miami Beach, Florida 33162, United States
  • Research Site
    Tampa, Florida 33624, United States
  • Research Site
    Arlington Hts, Illinois 60005, United States
  • Research Site
    Carmel, Indiana 46032, United States
  • Research Site
    Indianapolis, Indiana 46256, United States
  • Research Site
    Berlin, New Jersey 08009, United States
  • Research Site
    Charlotte, North Carolina 28277, United States
  • Research Site
    Portland, Oregon 97239, United States
  • Research Site
    ACT, 02606, Australia
  • Research Site
    Liverpool, 2170, Australia
  • Research Site
    Woolloongabba, 04102, Australia
  • Research Site
    Surrey, British Columbia V3R 6A7, Canada
  • Research Site
    Barrie, Ontario L4M 6L2, Canada
  • Research Site
    Quebec, G1V 4X7, Canada
  • Research Site
    Berlin, 10117, Germany
  • Research Site
    Frankfurt/Main, 60590, Germany
  • Research Site
    Gera, 07548, Germany
  • Research Site
    Hannover, 30625, Germany
  • Research Site
    Leipzig, 04103, Germany
  • Research Site
    München, 80337, Germany
  • Research Site
    Münster, 48149, Germany
  • Research Site
    Debrecen, 4032, Hungary
  • Research Site
    Kaposvár, 7400, Hungary
  • Research Site
    Miskolc, 3529, Hungary
  • Research Site
    Pécs, 7632, Hungary
  • Research Site
    Szeged, 6720, Hungary
  • Research Site
    Szombathely, 9700, Hungary
  • Research Site
    Tauranga, 3143, New Zealand
  • Research Site
    Wellington, 6021, New Zealand
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in May 2016, 8 months.

Results were first posted in Feb 2018, 1 year 9 months after primary completion. A results delay was requested in Jun 2017.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 8 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2015
First posted
Aug 17, 2015
StartActual
Aug 15, 2015
Primary completionActual
May 9, 2016
CompletionActual
Jul 15, 2016
Results delay requested
Jun 1, 2017
Results first posted
Feb 15, 2018
Last update
Feb 15, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02525094
Lead sponsor
MedImmune LLC
Collaborators
Amgen
Responsible party
Sponsor
First posted
Aug 17, 2015
Start date
Aug 15, 2015
Primary completion
May 9, 2016
Completion
Jul 15, 2016
Results posted
Feb 15, 2018
Last update
Feb 15, 2018

Study contacts

Eric Simpson, MD
principal investigator · Oregon Health and Science University
Roderick Mcphee, MD
study director · MedImmune LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tezepelumab

Start the discussion